The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Sci Transl Med 2012 Feb;4(119):119re1

Division of Biological Chemistry and Drug Discovery, Wellcome Trust Biocentre, College of Life Sciences, University of Dundee, Dundee, Scotland, UK.

Safer and more effective oral drugs are required to treat visceral leishmaniasis, a parasitic disease that kills 50,000 to 60,000 people each year in parts of Asia, Africa, and Latin America. Here, we report that fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis. This 2-substituted 5-nitroimidazole drug is rapidly oxidized in vivo in mice, dogs, and humans to sulfoxide and sulfone metabolites. Both metabolites of fexinidazole were active against Leishmania donovani amastigotes grown in macrophages, whereas the parent compound was inactive. Pharmacokinetic studies with fexinidazole (200 mg/kg) showed that fexinidazole sulfone achieves blood concentrations in mice above the EC(99) (effective concentration inhibiting growth by 99%) value for at least 24 hours after a single oral dose. A once-daily regimen for 5 days at this dose resulted in a 98.4% suppression of infection in a mouse model of visceral leishmaniasis, equivalent to that seen with the drugs miltefosine and Pentostam, which are currently used clinically to treat this tropical disease. In African trypanosomes, the mode of action of nitro drugs involves reductive activation via a NADH (reduced form of nicotinamide adenine dinucleotide)-dependent bacterial-like nitroreductase. Overexpression of the leishmanial homolog of this nitroreductase in L. donovani increased sensitivity to fexinidazole by 19-fold, indicating that a similar mechanism is involved in both parasites. These findings illustrate the potential of fexinidazole as an oral drug therapy for treating visceral leishmaniasis.

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3003326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457684PMC
February 2012
8 Reads

Publication Analysis

Top Keywords

visceral leishmaniasis
20
treating visceral
12
fexinidazole
7
visceral
5
leishmaniasis
5
oral dose
4
once-daily regimen
4
dose once-daily
4
single oral
4
hours single
4
concentration inhibiting
4
effective concentration
4
inhibiting growth
4
growth 99%
4
99% hours
4
regimen days
4
984% suppression
4
model visceral
4
leishmaniasis equivalent
4
equivalent drugs
4

References

(Supplied by CrossRef)

Raju et al.
Lancet 2000

Matlashewski et al.
The Lancet infectious diseases 2011

Croft et al.
Clinical Microbiology Reviews 2006

den Boer et al.
Expert opinion on emerging drugs 2009

Mueller et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene 2007

Barry et al.
Current pharmaceutical design 2004

Antimicrobial Agents and Chemotherapy 2009

Antimicrobial Agents and Chemotherapy 2008

Priotto et al.
Lancet 2009

Torreele et al.
2010

PNAS 2008

Similar Publications